Human Molecular Genetic and Functional Studies Identify TRIM63, Encoding Muscle RING Finger Protein 1, as a Novel Gene for Human Hypertrophic Cardiomyopathy

Rationale: A delicate balance between protein synthesis and degradation maintains cardiac size and function. TRIM63 encoding Muscle RING Finger 1 (MuRF1) maintains muscle protein homeostasis by tagging the sarcomere proteins with ubiquitin for subsequent degradation by the ubiquitin-proteasome system (UPS). Objective: To determine the pathogenic role of TRIM63 in human hypertrophic cardiomyopathy (HCM). Methods and Results: Sequencing of TRIM63 gene in 302 HCM probands (250 white individuals) and 339 control subjects (262 white individuals) led to identification of 2 missense (p.A48V and p.I130M) and a deletion (p.Q247*) variants exclusively in the HCM probands. These 3 variants were absent in 751 additional control subjects screened by TaqMan assays. Likewise, rare variants were enriched in the white HCM population (11/250, 4.4% versus 3/262, 1.1%, respectively, P=0.024). Expression of the mutant TRIM63 was associated with mislocalization of TRIM63 to sarcomere Z disks, impaired auto-ubiquitination, reduced ubiquitination and UPS-mediated degradation of myosin heavy chain 6, cardiac myosin binding protein C, calcineurin (PPP3CB), and p-MTOR in adult cardiac myocytes. Induced expression of the mutant TRIM63 in the mouse heart was associated with cardiac hypertrophy, activation of the MTOR-S6K and calcineurin pathways, and expression of the hypertrophic markers, which were normalized on turning off expression of the mutant protein. Conclusions: TRIM63 mutations, identified in patients with HCM, impart loss-of-function effects on E3 ligase activity and are probably causal mutations in HCM. The findings implicate impaired protein degradation in the pathogenesis of HCM.

[1]  杜昕,et al.  Inherited cardiomyopathies , 2012 .

[2]  Joseph K. Pickrell,et al.  A Systematic Survey of Loss-of-Function Variants in Human Protein-Coding Genes , 2012, Science.

[3]  A. Marian,et al.  Nuclear Plakoglobin Is Essential for Differentiation of Cardiac Progenitor Cells to Adipocytes in Arrhythmogenic Right Ventricular Cardiomyopathy , 2011, Circulation research.

[4]  H. Watkins,et al.  Disease pathways and novel therapeutic targets in hypertrophic cardiomyopathy. , 2011, Circulation research.

[5]  L. Carrier,et al.  The ubiquitin–proteasome system in cardiomyopathies , 2011, Current opinion in cardiology.

[6]  R. Austin,et al.  Interrelationship between cardiac hypertrophy, heart failure, and chronic kidney disease: endoplasmic reticulum stress as a mediator of pathogenesis. , 2011, Circulation research.

[7]  A. Marian Hypertrophic cardiomyopathy: from genetics to treatment , 2010, European journal of clinical investigation.

[8]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[9]  Thomas Eschenhagen,et al.  The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy. , 2010, Cardiovascular Research.

[10]  S. Lecker,et al.  Atrogin-1 and MuRF1 regulate cardiac MyBP-C levels via different mechanisms. , 2010, Cardiovascular research.

[11]  R. Reimer,et al.  Nonsense-Mediated mRNA Decay and Ubiquitin–Proteasome System Regulate Cardiac Myosin-Binding Protein C Mutant Levels in Cardiomyopathic Mice , 2009, Circulation research.

[12]  J. Schisler,et al.  Cardiac Muscle Ring Finger-1 Increases Susceptibility to Heart Failure In Vivo , 2009, Circulation research.

[13]  S. Gygi,et al.  During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation , 2009, The Journal of cell biology.

[14]  R. Schwartz,et al.  Genetic Fate Mapping Identifies Second Heart Field Progenitor Cells As a Source of Adipocytes in Arrhythmogenic Right Ventricular Cardiomyopathy , 2009, Circulation research.

[15]  I. Hisatome,et al.  Ubiquitin-proteasome system impairment caused by a missense cardiac myosin-binding protein C mutation and associated with cardiac dysfunction in hypertrophic cardiomyopathy. , 2008, Journal of molecular biology.

[16]  M. Willis,et al.  The ubiquitin-proteasome system in cardiac dysfunction. , 2008, Biochimica et biophysica acta.

[17]  O. Mayans,et al.  Structural analysis of B-Box 2 from MuRF1: identification of a novel self-association pattern in a RING-like fold. , 2008, Biochemistry.

[18]  Il-Jin Kim,et al.  FBXW7 Targets mTOR for Degradation and Cooperates with PTEN in Tumor Suppression , 2008, Science.

[19]  A. Marian,et al.  Differential interactions of thin filament proteins in two cardiac troponin T mouse models of hypertrophic and dilated cardiomyopathies. , 2008, Cardiovascular research.

[20]  A. Marian Genetic determinants of cardiac hypertrophy , 2008, Current opinion in cardiology.

[21]  V. Rybin,et al.  Muscle RING-finger protein-1 (MuRF1) as a connector of muscle energy metabolism and protein synthesis. , 2008, Journal of molecular biology.

[22]  S. Rakhilin,et al.  The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. , 2007, Cell metabolism.

[23]  Sanjay Shete,et al.  Genome-wide mapping of modifier chromosomal loci for human hypertrophic cardiomyopathy. , 2007, Human molecular genetics.

[24]  Mi-Sung Kim,et al.  Myosin accumulation and striated muscle myopathy result from the loss of muscle RING finger 1 and 3. , 2007, The Journal of clinical investigation.

[25]  H. Worman,et al.  "Laminopathies": a wide spectrum of human diseases. , 2007, Experimental cell research.

[26]  S. Shete,et al.  Myozenin 2 Is a Novel Gene for Human Hypertrophic Cardiomyopathy , 2007, Circulation research.

[27]  Cam Patterson,et al.  Muscle Ring Finger 1, but not Muscle Ring Finger 2, Regulates Cardiac Hypertrophy In Vivo , 2007, Circulation research.

[28]  C. Patterson,et al.  Into the heart: the emerging role of the ubiquitin-proteasome system. , 2006, Journal of molecular and cellular cardiology.

[29]  J. Molkentin,et al.  Regulation of cardiac hypertrophy by intracellular signalling pathways , 2006, Nature Reviews Molecular Cell Biology.

[30]  A. Marian,et al.  Antifibrotic effects of antioxidant N-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation. , 2006, Journal of the American College of Cardiology.

[31]  J. Robbins,et al.  Regulation of Transgene Expression Using Tetracycline , 2005, Current protocols in molecular biology.

[32]  Holly McDonough,et al.  Muscle ring finger protein-1 inhibits PKCε activation and prevents cardiomyocyte hypertrophy , 2004, The Journal of cell biology.

[33]  Cam Patterson,et al.  Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Da-Zhi Wang,et al.  Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. , 2004, The Journal of clinical investigation.

[35]  Q. Liang,et al.  Reengineering Inducible Cardiac-Specific Transgenesis With an Attenuated Myosin Heavy Chain Promoter , 2003, Circulation research.

[36]  Iacopo Olivotto,et al.  Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. , 2003, Journal of the American College of Cardiology.

[37]  M. Hochstrasser,et al.  Analysis of Protein Ubiquitination , 2002, Current protocols in protein science.

[38]  C. Gregorio,et al.  Muscle-specific RING finger-1 interacts with titin to regulate sarcomeric M-line and thick filament structure and may have nuclear functions via its interaction with glucocorticoid modulatory element binding protein-1 , 2002, The Journal of cell biology.

[39]  A. Goldberg,et al.  Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[40]  D J Glass,et al.  Identification of Ubiquitin Ligases Required for Skeletal Muscle Atrophy , 2001, Science.

[41]  K. Pelin,et al.  Identification of muscle specific ring finger proteins as potential regulators of the titin kinase domain. , 2001, Journal of molecular biology.

[42]  P. Elliott,et al.  Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy , 2001, The Lancet.

[43]  E. Lakatta,et al.  Erratum: Culture and adenoviral infection of adult mouse cardiac myocytes: Methods for cellular genetic physiology (American Journal of Physiology - Heart and Circulatory Physiology (July 2000) 279:48 (H429-H436)) , 2000 .

[44]  A. Weissman,et al.  RING Finger Proteins Mediators of Ubiquitin Ligase Activity , 2000, Cell.

[45]  E. Lakatta,et al.  Culture and adenoviral infection of adult mouse cardiac myocytes: methods for cellular genetic physiology. , 2000, American journal of physiology. Heart and circulatory physiology.

[46]  B. Maron,et al.  Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[47]  A. Marian,et al.  Expression of a mutant (Arg92Gln) human cardiac troponin T, known to cause hypertrophic cardiomyopathy, impairs adult cardiac myocyte contractility. , 1997, Circulation research.

[48]  D. Mann,et al.  Expression of a mutation causing hypertrophic cardiomyopathy disrupts sarcomere assembly in adult feline cardiac myocytes. , 1995, Circulation research.

[49]  P. Simpson,et al.  Stimulation of hypertrophy of cultured neonatal rat heart cells through an alpha 1-adrenergic receptor and induction of beating through an alpha 1- and beta 1-adrenergic receptor interaction. Evidence for independent regulation of growth and beating. , 1985, Circulation research.

[50]  H. Watkins,et al.  Inherited cardiomyopathies. , 2011, The New England journal of medicine.

[51]  R. Shephard Sudden Deaths in Young Competitive Athletes: Analysis of 1866 Deaths in the United States, 1980–2006 , 2010 .